Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) Stock
Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders.
Valuation
Financials & Margins
Valuation & Return Ratios
Ownership
About Zhejiang Ausun Pharmaceutical Co., Ltd.
Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customized contract research, development, and manufacturing services. In addition, the company engages in technology research and development, commissioned technology development, technology transfer, consulting, and promotion services; wholesale of organic intermediates; medical research and experimental development; market research; conference services; organization of exhibitions and displays; import and export trade of pharmaceuticals, food, cosmetics, medical devices, goods and technology, and related instruments and equipment; drug clinical trials; retail of pharmaceuticals; technical consultation and exchange; health consultation; and research and development of biochemical products. Zhejiang Ausun Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Taizhou, China.
Zhejiang Ausun Pharmaceutical Co., Ltd. is led by CEO Zhiguo Zheng, employs 1,328 people, headquartered in Taizhou, CN, publicly traded since 2017.
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) stock trades at $7.93 with a market capitalization of $6.58B. The stock is valued at a price-to-earnings (P/E) ratio of 72.09, price-to-book of 2.74, price-to-sales of 8.46. Over the past 52 weeks the stock has ranged between $7.15 and $10.81, and currently trades 26.6% below its 52-week high. It pays a dividend yielding 0.80%.
On profitability, Zhejiang Ausun Pharmaceutical Co., Ltd. generates a return on equity (ROE) of 3.37%, an operating margin of -4.37%, a net profit margin of 10.41%.
Official website: www.ausunpharm.com
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) — frequently asked questions
What is Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) stock price today?
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) is currently trading at $7.93, down 1% today.
What is 603229.SS P/E ratio?
Zhejiang Ausun Pharmaceutical Co., Ltd.'s P/E ratio is 72.09. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.
What is 603229.SS return on equity (ROE)?
Zhejiang Ausun Pharmaceutical Co., Ltd.'s return on equity (ROE) is 3.37%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.
What is Zhejiang Ausun Pharmaceutical Co., Ltd.'s market cap?
Zhejiang Ausun Pharmaceutical Co., Ltd. has a market capitalization of $6.58B.
Does 603229.SS pay a dividend?
Yes. Zhejiang Ausun Pharmaceutical Co., Ltd. currently yields 0.80%. Yield moves with the share price, so it changes daily even when the payment does not.
How much debt does 603229.SS carry?
Zhejiang Ausun Pharmaceutical Co., Ltd. has a debt-to-equity ratio of 0.15. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 603229.SS's profit margin?
Zhejiang Ausun Pharmaceutical Co., Ltd. reports a net profit margin of 10.41% — the share of revenue left after every cost, including tax and interest.
What sector is 603229.SS in?
Zhejiang Ausun Pharmaceutical Co., Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 603229.SS listed on?
Zhejiang Ausun Pharmaceutical Co., Ltd. trades on SHH under the ticker 603229.SS.
What is 603229.SS's 52-week range?
Over the last year Zhejiang Ausun Pharmaceutical Co., Ltd. has traded between $7.15 and $10.81.
Related Healthcare Stocks
Popular Stocks
Screens 603229.SS currently matches
On the figures above, Zhejiang Ausun Pharmaceutical Co., Ltd. passes the filters for 8 of our ready-made screens, among them Low Debt Stocks, Stocks Under $10, High PE Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.